Question from Deputy Ken O'Flynn - PQ 28068-26
Deputy O'Flynn asked about any audit or validation exercise has been conducted on the accuracy/consistency of claim rejections by PCRS. Read the HSE response.
- Published date:
- :
Corporate publications
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Showing 3101 to 3110 of 8945 results
Question from Deputy Ken O'Flynn - PQ 28143-26
Deputy O'Flynn asked about the waiting lists for Children’s Disability Network Teams (CDNTs). Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28065-26
Deputy O'Flynn asked if rejected/unpaid claims for salbutamol nebules (2024/25) can be disaggregated from general rejection categories. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28039-26
Deputy O'Flynn asked about alerts to identify significant increases in spend on specific medicines, including salbutamol nebules. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28041-26
Deputy O'Flynn asked about whether benchmarking has been carried out comparing expenditure and utilisation of salbutamol nebules. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28109-26
Deputy O'Flynn asked about the treatment abroad scheme records total cost per patient episode since 2020. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28064-26
Deputy O'Flynn asked if PCRS maintains product-specific data on rejected or unpaid pharmacy claims. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28034-26
Deputy O'Flynn asked about the reimbursement price per unit applicable to salbutamol nebules under PCRS 2024-2026. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28036-26
Deputy O'Flynn asked why the PCRS does not capture or retain data on the clinical indication associated with medicines reimbursed. Read the HSE response.
- Published date:
- :
Question from Deputy Ken O'Flynn - PQ 28037-26
Deputy O'Flynn asked about analysis on the change in seasonal expenditure patterns for salbutamol nebules between 2024 and 2025. Read the HSE response.
- Published date:
- :